Semaglutides cardiovascular outcomes trials (such as the SUSTAIN and SELECT programmes) have generally shown neutral or beneficial effects on major cardiovascular outcomes and no significant increase in clotting events compared to placebo
I contacted them & they answered all my questions and put me on a perfect matched therapy
Malaguarnera M, Gargante MP, Russo C, Antic T, Vacante M, Malaguarnera M, et al
Semaglutide comes in four FDA-approved brand-name products: Wegovy (weekly injection, 1.7 mg / 2.4 mg / 7.2 mg) chronic weight management
In the 12mg arm, some participants lost over 30% of their body weight while others lost under 15%
Tirzepatide is commonly studied as a subcutaneous injection taken on a scheduled basis